Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Adaptimmune Therapeutics Plc Stock Quote

Adaptimmune Therapeutics Plc (NASDAQ: ADAP)

$1.05
(-9.5%)
-$0.11
Price as of April 15, 2024, 4:00 p.m. ET

Adaptimmune Therapeutics Plc Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ADAP -22.79% -75.52% -24.53% -94%
S&P +22.34% +74.52% +11.78% +142%

Adaptimmune Therapeutics Plc Company Info

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the provision and development of novel cell therapies and novel cancer immunotherapy products to people with cancer. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.